Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT

Daniels J, Middleton LJ, Cheed V, McKinnon W, Rana D, Sirkeci F, Manyonda I, Belli AM, Lumsden MA, Moss J, Wu O, McPherson K
Record ID 32011000718
English
Original Title: FEMME trial: Randomised trial of treating Fibroids with either Embolisation or MyoMectomy to measure the Effect on quality of life
Authors' objectives: Uterine fibroids are the most common tumour in women of reproductive age and are associated with heavy menstrual bleeding, abdominal discomfort, subfertility and reduced quality of life. For women wishing to retain their uterus and who do not respond to medical treatment, myomectomy and uterine artery embolisation are therapeutic options. We examined the clinical effectiveness and cost-effectiveness of uterine artery embolisation compared with myomectomy in the treatment of symptomatic fibroids.
Details
Project Status: Completed
URL for project: https://www.journalslibrary.nihr.ac.uk/programmes/hta/085322/#/
Year Published: 2022
URL for published report: https://www.journalslibrary.nihr.ac.uk/hta/ZDEG6110
Requestor: NIHR Health Technology Assessment programme
URL for additional information: https://www.journalslibrary.nihr.ac.uk/hta/ZDEG6110
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England, United Kingdom
MeSH Terms
  • Female
  • Leiomyoma
  • Quality of Life
  • Uterine Artery Embolization
  • Uterine Myomectomy
  • Uterine Neoplasms
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.